Cascade Investment Advisors Inc. Purchases 665 Shares of Bristol-Myers Squibb (NYSE:BMY)

Cascade Investment Advisors Inc. lifted its position in Bristol-Myers Squibb (NYSE:BMYGet Rating) by 2.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,000 shares of the biopharmaceutical company’s stock after acquiring an additional 665 shares during the quarter. Cascade Investment Advisors Inc.’s holdings in Bristol-Myers Squibb were worth $1,746,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. OLD Mission Capital LLC bought a new position in Bristol-Myers Squibb in the third quarter worth about $234,000. EagleClaw Capital Managment LLC raised its holdings in Bristol-Myers Squibb by 2.9% in the third quarter. EagleClaw Capital Managment LLC now owns 64,447 shares of the biopharmaceutical company’s stock worth $3,823,000 after purchasing an additional 1,800 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Bristol-Myers Squibb by 541.0% in the third quarter. Massachusetts Financial Services Co. MA now owns 42,160 shares of the biopharmaceutical company’s stock worth $2,495,000 after purchasing an additional 35,583 shares in the last quarter. O Shaughnessy Asset Management LLC raised its holdings in Bristol-Myers Squibb by 14.6% in the third quarter. O Shaughnessy Asset Management LLC now owns 280,630 shares of the biopharmaceutical company’s stock worth $16,605,000 after purchasing an additional 35,851 shares in the last quarter. Finally, Rafferty Asset Management LLC raised its holdings in Bristol-Myers Squibb by 54.5% in the third quarter. Rafferty Asset Management LLC now owns 82,990 shares of the biopharmaceutical company’s stock worth $4,911,000 after purchasing an additional 29,273 shares in the last quarter. Hedge funds and other institutional investors own 73.07% of the company’s stock.

NYSE BMY traded down $0.50 during trading hours on Friday, reaching $75.80. The stock had a trading volume of 13,773,108 shares, compared to its average volume of 14,853,342. The stock has a fifty day moving average of $74.15 and a 200 day moving average of $66.36. The stock has a market cap of $161.38 billion, a P/E ratio of 26.88, a price-to-earnings-growth ratio of 1.61 and a beta of 0.49. Bristol-Myers Squibb has a 52-week low of $53.22 and a 52-week high of $78.17. The company has a debt-to-equity ratio of 1.18, a quick ratio of 1.23 and a current ratio of 1.32.

Bristol-Myers Squibb (NYSE:BMYGet Rating) last released its quarterly earnings data on Friday, April 29th. The biopharmaceutical company reported $1.96 EPS for the quarter, topping the consensus estimate of $1.91 by $0.05. Bristol-Myers Squibb had a return on equity of 48.37% and a net margin of 13.31%. The business had revenue of $11.65 billion for the quarter, compared to analyst estimates of $11.34 billion. During the same quarter in the prior year, the firm posted $1.74 EPS. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. On average, equities research analysts forecast that Bristol-Myers Squibb will post 7.57 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Monday, May 2nd. Shareholders of record on Friday, April 1st were given a $0.54 dividend. The ex-dividend date was Thursday, March 31st. This represents a $2.16 annualized dividend and a yield of 2.85%. Bristol-Myers Squibb’s dividend payout ratio is presently 76.60%.

A number of brokerages have recently weighed in on BMY. Barclays boosted their price target on Bristol-Myers Squibb from $66.00 to $68.00 in a research note on Monday, May 2nd. BMO Capital Markets boosted their price target on Bristol-Myers Squibb from $87.00 to $92.00 in a research note on Monday, May 2nd. StockNews.com began coverage on Bristol-Myers Squibb in a research note on Thursday, March 31st. They set a “strong-buy” rating on the stock. Guggenheim boosted their price target on Bristol-Myers Squibb from $72.00 to $80.00 in a research note on Monday, May 2nd. Finally, Truist Financial boosted their price target on Bristol-Myers Squibb from $76.00 to $81.00 in a research note on Monday, May 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $71.33.

In other Bristol-Myers Squibb news, CEO Giovanni Caforio sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, February 24th. The stock was sold at an average price of $67.00, for a total value of $2,010,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Rupert Vessey sold 74,559 shares of the company’s stock in a transaction that occurred on Wednesday, March 16th. The stock was sold at an average price of $69.25, for a total value of $5,163,210.75. The disclosure for this sale can be found here. In the last 90 days, insiders sold 165,668 shares of company stock worth $11,459,888. Insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Profile (Get Rating)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.

Read More

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.